Profile

William Henry Gmeiner, Ph.D.Wake Forest School of Medicine

William Henry Gmeiner, Ph.D.

Professor,

Contact Information

Academic: 336-716-6216 | Department: 336-716-6216

Email: bgmeiner@wakehealth.edu

Education & Training

  • B.A., University of Chicago, 1982
  • Ph.D., University of Utah, 1989
  • M.B.A., Wake Forest University, 2007
  • Fellowship, University Alberta Medical Sch, 1991

Memberships

  • Am Assn Of Cancer Research
  • Am Chemical Society
  • Am Soc for Pharm & Exper Ther
William Henry Gmeiner, Ph.D.

William Henry Gmeiner, Ph.D.

Professor, Cancer Biology
Physiology & Pharmacology

Research Interests

DNA; Fluorodeoxyuridylate; Antineoplastic Agents; Fluorouracil; Antimetabolites, Antineoplastic
More »

Contact Information

Academic: 336-716-6216 | Department: 336-716-6216

Email: bgmeiner@wakehealth.edu

Recent Publications

Importance of long-time simulations for rare event sampling in zinc finger proteins. Godwin R, Gmeiner W, Salsbury FR Jr.. J Biomol Struct Dyn. 2016;34(1):125-134.

Prostate-specific membrane antigen-targeted liposomes specifically deliver the Zn(2+) chelator TPEN inducing oxidative stress in prostate cancer cells. Stuart CH, Singh R, Smith TL, D'Agostino R Jr, Caudell D, Balaji KC, Gmeiner WH.. Nanomedicine (Lond). 2016;11(10):1207-1222.

The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS.. Future Oncol. 2016;():.

F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death. Gmeiner WH, Gearhart PJ, Pommier Y, Nakamura J.. Future Oncol. 2016;():.

The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2. Gmeiner WH, Boyacioglu O, Stuart CH, Jennings-Gee J, Balaji KC.. Prostate. 2015;75(4):360-369.

Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. Gmeiner WH, Jennings-Gee J, Stuart CH, Pardee TS.. Leuk Res. 2015;39(2):229-235.

Influence of zinc-binding on folding and dynamics of zinc finger proteins: in silico [abstract]. Godwin R, Gmeiner W, Salsbury F.. Biophys J. 2015;108(2 Suppl 1):519A.

Small Fdu strand exhibits salt-dependent stability [abstract]. Melvin RL, Gmeiner W, Salsbury FR.. Biophys J. 2015;108(2 Suppl 1):237A.

Disease related mutation effects on conformations and dynamics of the zinc-finger NEMO [abstract]. Godwin R, Gmeiner W, Salsbury F.. Protein Sci. 2015;24(Suppl 1):164-165.

Site-specific DNA-doxorubicin conjugates display enhanced cytotoxicity to breast cancer cells. Stuart CH, Horita DA, Thomas MJ, Salsbury FR Jr, Lively MO, Gmeiner WH.. Bioconjug Chem. 2014;25(2):406-413.

Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, Debinski W.. J Neurooncol. 2014;116(3):447-454.

Non-covalent assembly of meso-tetra-4-pyridyl porphine with single-stranded DNA to form nano-sized complexes with hydrophobicity-dependent DNA release and anti-tumor activity. Ghosh S, Ucer KB, D'Agostino R Jr, Grant K, Sirintrapun J, Thomas MJ, Hantgan R, Bharadwaj M, Gmeiner WH.. Nanomedicine (Lond). 2014;10(2):451-461.

The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH.. Oncotarget. 2014;5(12):4170-4179.

Nanotechnology for cancer treatment. Gmeiner WH, Ghosh S.. Nanotechnology Rev. 2014;3(2):111-122.

F10 inhibits growth of PC3 xenografts and enhances the effects of radiation therapy. Gmeiner WH, Willingham MC, Bourland JD, Hatcher HC, Smith TL, D'Agostino RB Jr, Blackstock W.. J Clin Oncol Res. 2014;2(4):1028.

Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Jennings-Gee J, Pardee TS, Gmeiner WH.. Exp Hematol. 2013;41(2):180-188.

Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity. Wu SY, Chen TM, Gmeiner WH, Chu E, Schmitz JC.. Nucleic Acids Res. 2013;41(8):4650-4659.

Dimeric DNA aptamer complexes for high-capacity-targeted drug delivery using pH-sensitive covalent linkages. Boyacioglu O, Stuart CH, Kulik G, Gmeiner WH.. Mol Ther Nucleic Acids. 2013;2():e107.

Cooperative stabilization of Zn(2+):DNA complexes through netropsin binding in the minor groove of FdU-substituted DNA. Ghosh S, Salsbury FR Jr, Horita DA, Gmeiner WH.. J Biomol Struct Dyn. 2013;31(11):1301-1310.

TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs. Huang SY, Murai J, Dalla Rosa I, Dexheimer TS, Naumova A, Gmeiner WH, Pommier Y.. Nucleic Acids Res. 2013;41(16):7793-7803.

Non-covalent assembly of meso-tetra-4-pyridyl porphine with single-stranded DNA to form nano-sized complexes with pH-dependent DNA release and anti-tumor activity [abstract]. Gmeiner WH, Ghosh S, Ucer KB, Williams RT, D'Agostino R, Grant K, Sirintrapun J, Thomas M, Hantgan R, Bharadwaj M.. Cancer Res. 2013;73(8 Suppl 1):ALB-6.

Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH.. Blood. 2012;119(15):3561-3570.

Carbon nanotubes for cancer therapy. Gmeiner WH. In: Kumar CSSR, ed. Carbon nanomaterials. Weinheim (Germany): Wiley-VCH;2011: 309-332.

Zn2+ selectively stabilizes FdU-substituted DNA through a unique major groove binding motif. Ghosh S, Salsbury FR Jr, Horita DA, Gmeiner WH.. Nucleic Acids Res. 2011;39(10):4490-4498.

The stability of a model substrate for topoisomerase 1-mediated DNA religation depends on the presence of mismatched base pairs. Gmeiner WH, Salsbury F Jr, Olsen CM, Marky LA.. J Nucleic Acids. 2011;2011():631372.

Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP10 results in high efficacy against AML and low toxicity [abstract]. Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W.. Blood. 2011;118(21):1109-1110.

Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Gmeiner WH, Reinhold WC, Pommier Y.. Mol Cancer Ther. 2010;9(12):3105-3114.

The novel fluoropyrimidine FdUMP[10] is highly active against acute myeloid leukemia [abstract]. Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W.. Blood. 2010;116(21):1353.

Increased heating efficiency and selective thermal ablation of malignant tissue with DNA-encased multiwalled carbon nanotubes. Ghosh S, Dutta S, Gomes E, Carroll D, D'Agostino R Jr, Olson J, Guthold M, Gmeiner WH.. ACS Nano. 2009;3(9):2667-2673.

Tissue-dependent and -independent gene expression changes in metastatic colon cancer. Gmeiner WH, Hellmann GM, Shen P.. Oncol Rep. 2008;19(1):245-251.

MicroPET imaging to monitor tumor response to single agent and combined ionizing radiation therapy and FdUMP treatment [abstract]. Gmeiner WH, Garg S, Hatcher HC, Smith TL, Bourland JD, Garg PK.. J Nucl Med. 2007;48(6 Suppl 2):83P.

Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. Bijnsdorp IV, Comijn EM, Padron JM, Gmeiner WH, Peters GJ.. Oncol Rep. 2007;18(1):287-291.

Genetic determinants for activated fluoropyrimidine chemotherapy. Gmeiner WH.. Drug Dev Res. 2006;67(2):119-129.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Cancer Biology

William Henry Gmeiner, Ph.D.

William Henry Gmeiner, Ph.D.

Professor, Cancer Biology
Physiology & Pharmacology

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.